Article Figures & Data
Figures
- Figure 1.
Entheses (combination of SPARCC, LEI, and MASES) examined in the study. LEI: Leeds Enthesitis Index; MASES: Maastricht Ankylosing Spondylitis Enthesitis Score; SPARCC: Spondyloarthritis Research Consortium of Canada.
Tables
Values Age, yrs 49.02 (13.12) Males, n (%) 272 (51.71) Duration of PsA, yrs 10.74 (10.73) BMI, kg/m2 29.13 (6.25) PASI 4.26 (8.38) Enthesitis score, median (IQR) 2 (1-2) Time of enthesitis onset to resolution, months 8.73 (3.48) Swollen joint count 3.30 (5.54) Tender joint count 7.72 (9.83) Actively inflamed joint counta 8.88 (10.55) Damaged joint count 4.09 (8.38) Axial diseaseb, n (%) (N = 476) 141 (29.62) Dactylitis, n (%) 108 (20.53) Nail lesions at baseline, n (%) 287 (54.56) Fibromyalgia at baseline, n (%) 127 (24.14) Baseline enthesitis year, n (%) 2000-2004 118 (22.43) 2005-2009 137 (26.05) 2010-2014 129 (24.52) > 2015 142 (27.00) Values are expressed as mean (SD) unless indicated otherwise.
↵aActively inflamed joint count is the sum of tender and/or swollen joints.
↵bAxial disease was defined as patients fulfilling the radiographic arm of the modified New York ankylosing spondylitis criteria (≥ bilateral grade 2 sacroiliitis or unilateral grade 3 or 4). PASI: Psoriasis Area and Severity Index.
- Table 2.
Number of patients in each category of medications with details of resolution of enthesitis (N = 526).
Medications in Each Category n (%) No. of Patients on
Each Medication (%)Average Time on
Treatment, Years (SD)Resolution of Enthesitis, n (%) Yes No Category I 142 (27.00) 2.58 (3.69) 117 (82.39) 25 (17.61) No medication 52 (36.66) NA NSAID 90 (63.38) 2.58 (3.69) Category II 196 (37.26) 3.06 (4.58) 173 (88.26) 23 (11.73) Methotrexate 150 (76.53)a 2.93 (4.61) Leflunomide 29 (14.79) 1.74 (2.82) Sulfasalazine 32 (16.32) 2.69 (3.50) Azathioprine 10 (5.10) 5.82 (7.00) Cyclosporine 2 (1.02) 2.34 (0.33) Category III 188 (35.74) 1.72 (2.23) 163 (86.70) 25 (13.30) Targeted bDMARDs TNFib 155 (82.45) 1.86 (2.39) IL-17ic 14 (7.44) 1.18 (1.09) IL-12/23i, IL-23i 18 (9.57) 0.94 (0.97) Targeted sDMARDs PDE-5i (Apremilast) 1 (0.50) – JAKi (Tofacitinib) 0 (0) – Total patients with and without
resolution of enthesitis453 (86.12) 73 (13.88) Male 240 (52.98) 41 (56.16) Females 213 (47.02) 32 (43.83) ↵aPercentage of individual medications do not add to 100 as some patients were on combination cDMARDs.
↵bIncludes etanercept, adalimumab, infliximab, golimumab, and certolizumab pegol.
↵cIncludes secukinumab and ixekizumab. bDMARD: biologic disease-modifying antirheumatic drug; IL-17i: interleukin 17 inhibitor; IL-12/23i: interleukin 12/23 inhibitor; JAKi: Janus kinase inhibitor; NA: not applicable; NSAID: nonsteroidal antiinflammatory drug; PDE-5i: phosphodiesterase-5 inhibitor; sDMARD: synthetic disease-modifying antirheumatic drug; TNFi: tumor necrosis factor inhibitor.
Univariable Model Multivariable Model OR (95% CI) P OR (95% CI) P Sex, male 1.61 (0.97-2.68) 0.07 1.66 (0.97-2.84) 0.06 Baseline age, yrs 1.00 (0.98-1.02) 0.85 1.00 (0.98-1.02) 0.98 Baseline PsA duration, yrs 1.00 (0.98-1.03) 0.81 1.00 (0.97-1.03) 0.99 Baseline enthesitis count 0.96 (0.87-1.06) 0.45 0.97 (0.87-1.09) 0.65 Baseline actively inflamed joint count 0.98 (0.96-1.00) 0.03 0.97 (0.95-0.99) 0.01 BMI, kg/m2 1.01 (0.97-1.05) 0.69 1.02 (0.97-1.06) 0.49 Nail lesions 1.26 (0.76-2.08) 0.37 1.27 (0.75-2.15) 0.38 Fibromyalgia 1.01 (0.56-1.82) 0.97 1.31 (0.69-2.47) 0.41 Medication category 0.58* 0.43* Category I Ref Ref Ref Ref Category II 1.40 (0.74-2.63) 0.30 1.51 (0.78-2.91) 0.30 Category III 1.24 (0.67-2.31) 0.50 1.42 (0.74-2.71) 0.22 ↵*Global P value. OR: odds ratio; PsA: psoriatic arthritis.
